Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
Go back to Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma| (NASDAQ: ALLO) | Delayed: 2.05 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.05 | 52 Week High | $ | |||
| Open | $2.05 | 52 Week Low | $ | |||
| Day High | $2.05 | P/E | N/A | |||
| Day Low | $2.05 | EPS | $ | |||
| Volume | 5,006 | |||||
